National Malaria Control Program Pharmaceutical Import Profile — Sierra Leone (DGFT 2022–2026)

Name: National Malaria Control Program Pharmaceutical Import Records from India — 2 Products, $600.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

National Malaria Control Program — Pharmaceutical Importer Profile (2026) | 2 Products, $600.0K Trade | TransData Nexus

National Malaria Control Program

Pharmaceutical Importer · Sierra Leone · Antimalarial & Antiparasitic Focus · $600.0K Total Trade · DGFT Verified

National Malaria Control Program is a pharmaceutical importer based in Sierra Leone with a total trade value of $600.0K across 2 products in 1 therapeutic categories. Based on 12 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. National Malaria Control Program sources from 2 verified Indian suppliers, with Macleods Pharmaceuticals Limited accounting for 82.1% of imports.

National Malaria Control Program — Import Portfolio & Supplier Network

National Malaria Control Program import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to National Malaria Control Program?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$272.6K	6	82.1%
Strides Pharma Science Limited	$59.6K	2	17.9%

National Malaria Control Program sources from 2 verified Indian suppliers across .

What Formulations Does National Malaria Control Program Import?

Formulation	Value	Ships
Sulfadoxine 250MG/pyrimethamine 12.5MG tablet	$150.0K	3
Sulfadoxine/pyrimethamine 250MG/12.5MG tablet	$122.6K	3
Combiart artemether and lumefantrine tablets [20MG/120MG](6376.00x 30 x 18's	$50.0K	1
Artecap artesunate rectal capsules [100MG][soft gelatin] 16900 pac x 1 x 2's Each soft gelatin capsule contains	$9.6K	1

National Malaria Control Program imports 4 distinct pharmaceutical formulations. Showing top 4 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pyrimethamine	Antimalarial & Antiparasitic	$300.0K	6	0.6%	12
2	Sulfadoxine	Antimalarial & Antiparasitic	$300.0K	6	0.6%	11

National Malaria Control Program imports 2 pharmaceutical products across 1 categories into Sierra Leone totaling $600.0K.

National Malaria Control Program — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The National Malaria Control Programme (NMCP) is a government initiative under Sierra Leone's Ministry of Health and Sanitation, dedicated to eradicating malaria within the country. As a public health entity, NMCP is not a commercial pharmaceutical buyer or importer but serves as the primary agency responsible for coordinating and implementing malaria control strategies, including the procurement and distribution of antimalarial medications. The program's headquarters are located in Freetown, Sierra Leone's capital. NMCP collaborates with various stakeholders, including international organizations and local health authorities, to reduce the malaria burden through interventions such as insecticide-treated nets, indoor residual spraying, and effective case management. Their role in Sierra Leone's pharmaceutical distribution is pivotal, ensuring the availability and proper distribution of antimalarial drugs to health facilities nationwide. (nmcp-moh.gov.sl)

2Distribution Network

NMCP's distribution network is extensive, encompassing all districts in Sierra Leone to ensure equitable access to malaria control interventions. While specific warehouse locations are not publicly detailed, the program operates through a centralized system that coordinates with regional health offices and local health facilities. This structure facilitates the efficient distribution of antimalarial medications and other malaria control tools. Logistically, NMCP leverages the country's transportation infrastructure, including road networks and maritime routes, to reach both urban and remote rural areas. Their geographic coverage is nationwide, aiming to provide comprehensive malaria control services across Sierra Leone. (nmcp-moh.gov.sl)

3Industry Role

In Sierra Leone's pharmaceutical supply chain, NMCP functions as the central procurer and distributor of antimalarial medications. Unlike commercial entities, NMCP's role is not that of a wholesaler or parallel importer; instead, it is a government agency responsible for the strategic procurement and distribution of malaria-related pharmaceuticals. This centralized approach ensures that antimalarial drugs are distributed based on public health priorities rather than market dynamics, aiming to reduce the malaria burden effectively. NMCP's activities are closely coordinated with the Pharmacy Board of Sierra Leone, which regulates the importation and quality control of pharmaceuticals in the country. (pharmacyboard.gov.sl)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — National Malaria Control Program

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

NMCP's procurement strategy for antimalarial medications appears to be highly concentrated, with a significant portion of imports sourced from India. This concentration suggests a strategic choice to leverage cost-effective and reliable suppliers. The data indicates that NMCP imported finished pharmaceutical formulations, specifically Pyrimethamine and Sulfadoxine, totaling $600,000 USD across 12 shipments from two Indian suppliers: MACLEODS PHARMACEUTICALS LIMITED and STRIDES PHARMA SCIENCE LIMITED. MACLEODS PHARMACEUTICALS LIMITED accounted for 82.1% of these shipments, while STRIDES PHARMA SCIENCE LIMITED contributed 17.9%. This supplier concentration may pose risks related to supply chain disruptions or changes in supplier reliability. However, the consistent sourcing from these suppliers over multiple shipments suggests a stable and ongoing relationship, indicating that NMCP has established dependable procurement channels. The absence of alternative suppliers in the data highlights a potential area for diversification to mitigate risks associated with over-reliance on a limited number of suppliers.

2Supply Chain Resilience

The resilience of NMCP's supply chain, particularly concerning its Indian suppliers, is a critical factor in ensuring the uninterrupted availability of antimalarial medications. The data reveals that NMCP has engaged with two Indian suppliers for its antimalarial imports, indicating a degree of diversification. However, the dominance of MACLEODS PHARMACEUTICALS LIMITED, which supplied 82.1% of the shipments, suggests a reliance on a single source for the majority of supplies. This concentration could expose NMCP to risks such as supply disruptions due to manufacturing issues, regulatory changes, or geopolitical factors affecting trade between India and Sierra Leone. The limited number of suppliers also suggests a lack of backup options, which could be problematic in the event of unforeseen disruptions. To enhance supply chain resilience, NMCP might consider diversifying its supplier base and establishing relationships with additional manufacturers to ensure a more robust and flexible supply chain.

Importing Pharmaceuticals into Sierra Leone — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sierra Leone

1Regulatory Authority & Framework

In Sierra Leone, the Pharmacy Board of Sierra Leone (PBSL) serves as the primary regulatory authority overseeing the importation, distribution, and quality control of pharmaceuticals. Established under the Pharmacy and Drugs Act of 2001, PBSL is responsible for ensuring that all pharmaceutical products meet national and international standards of quality, safety, and efficacy. The PBSL operates under the Ministry of Health and Sanitation and collaborates with other governmental and international bodies to regulate the pharmaceutical sector effectively. Key legislation governing pharmaceutical imports includes the Pharmacy and Drugs Act, which outlines the requirements for drug registration, import permits, and compliance with Good Manufacturing Practices (GMP). The PBSL's role is critical in maintaining the integrity of the pharmaceutical supply chain and safeguarding public health in Sierra Leone. (pharmacyboard.gov.sl)

2Import Licensing & GMP

Import licensing in Sierra Leone is governed by the Pharmacy and Drugs Act, which mandates that all pharmaceutical products imported into the country must be registered with the PBSL. Importers are required to obtain import permits and clearance permits before bringing pharmaceutical products into Sierra Leone. These permits ensure that imported drugs comply with national regulatory standards and are safe for public use. The PBSL also enforces compliance with Good Manufacturing Practices (GMP) to ensure that pharmaceutical products meet quality standards. GMP certificates from recognized authorities, such as the World Health Organization (WHO), are typically recognized by the PBSL. Importers must ensure that their suppliers adhere to these standards to facilitate the importation process. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Sierra Leone. (pharmacyboard.gov.sl)

National Malaria Control Program — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

NMCP's focus on antimalarial and antiparasitic medications aligns with Sierra Leone's public health priorities, given the high prevalence of malaria in the country. The program's procurement strategy emphasizes the importation of Pyrimethamine and Sulfadoxine, which are essential components in the treatment of malaria. The market demand for these products is driven by the need to provide effective treatment options to the population, particularly in areas with high transmission rates. By concentrating on these specific therapeutic areas, NMCP aims to reduce the malaria burden and improve health outcomes across Sierra Leone. (nmcp-moh.gov.sl)

2Sourcing Profile

NMCP's sourcing strategy for antimalarial medications is centered on importing finished pharmaceutical formulations from India, a country known for its robust pharmaceutical manufacturing sector. The program's focus on finished formulations indicates a preference for ready-to-use products that meet international quality standards. India's established pharmaceutical industry, with its adherence

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — National Malaria Control Program

What products does National Malaria Control Program import from India?

National Malaria Control Program imports 2 pharmaceutical products across 1 categories. Top imports: Pyrimethamine ($300.0K), Sulfadoxine ($300.0K).

Who supplies pharmaceuticals to National Malaria Control Program from India?

National Malaria Control Program sources from 2 verified Indian suppliers. The primary supplier is Macleods Pharmaceuticals Limited (82.1% of imports, $272.6K).

What is National Malaria Control Program's total pharmaceutical import value?

National Malaria Control Program's total pharmaceutical import value from India is $600.0K, based on 12 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does National Malaria Control Program focus on?

National Malaria Control Program imports across 1 categories. The largest: Antimalarial & Antiparasitic (100.0%).

Get Full National Malaria Control Program Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.